Methylation Amplicon Sequencing

Methylation Amplicon Sequencing

1. Background

DNA methylation plays a critical role in the regulation of gene expression and in disease initiation and progression. Aberrant methylation at specific genes or genomic regions is closely associated with a wide range of diseases. Methylation Amplicon Sequencing (Bisulfite Amplicon Sequencing, BSAS) employs target-specific primers to perform directed amplification and deep sequencing of genes or regions of interest, enabling precise quantitative analysis of methylation status in candidate regions.

This technology combines the single-base resolution advantages of bisulfite conversion with the targeting precision of PCR amplification, enabling detection of methylation differences at individual CpG site resolution. Compared to whole-genome methylation approaches, amplicon sequencing offers lower cost, higher throughput, and greater sequencing depth, making it particularly well-suited for large-sample candidate gene validation and clinical biomarker research.

With the advancement of precision medicine, DNA methylation biomarkers have demonstrated tremendous value in tumor early screening, disease diagnosis, prognosis evaluation, and drug response prediction. Methylation amplicon sequencing provides a reliable, economical, and high-throughput detection solution for these clinical applications, and has become an important tool for translational epigenetics research.

2. Detection Principle

The core principle of methylation amplicon sequencing is the integration of bisulfite conversion technology with multiplex PCR amplification to achieve targeted methylation detection at specific genomic regions. Genomic DNA is first treated with bisulfite, converting unmethylated cytosines (C) to uracil (U), while 5-methylcytosine remains unchanged.

The workflow includes: designing conversion-specific primers for the target regions — primer design must avoid CpG sites to ensure equivalent amplification efficiency for both methylated and unmethylated templates; performing multiplex PCR amplification of the converted DNA, with 8–96 target regions amplifiable simultaneously; purifying the amplification products and constructing sequencing libraries for high-throughput sequencing; and conducting bioinformatic analysis to align sequencing reads to the reference sequences and calculate the methylation proportion at each CpG site.

The key advantage of this method is that it achieves ultra-high sequencing depth (typically >5,000X), enabling accurate detection of low-frequency methylation events and subtle inter-sample differences. Individual amplicons are typically 150–500 bp in length, with each amplicon containing several to dozens of CpG sites, providing detailed information on intra-regional methylation patterns.

3. Technology Innovation and Advantages

3.1 Intelligent Primer Design System

A professional primer design platform has been developed to ensure detection accuracy:

(1) CpG-avoidance design: Primer binding regions are designed to avoid CpG dinucleotides, ensuring equivalent amplification of both methylated and unmethylated templates.

(2) Amplification efficiency optimization: In silico prediction of primer specificity and amplification efficiency to prevent primer-dimer formation and non-specific amplification.

(3) Multiplex compatibility design: For multiplex PCR panels, inter-primer compatibility is optimized to ensure balanced amplification across all targets.

(4) Flexible panel configuration: Supports single-gene fine-scale analysis (tiling design) or multi-gene panels (8–96 targets).

3.2 Ultra-Deep Sequencing Strategy

A high-depth sequencing strategy is employed to achieve precise quantification:

Sequencing depth >5,000X per amplicon; critical sites can reach 10,000–50,000X.

High-depth coverage enables methylation quantification error <1%, with the ability to detect methylation differences as low as 1–2%.

Applicable to low-frequency methylation detection in heterogeneous samples (e.g., tumor tissue, circulating tumor DNA).

Supports single-cell level methylation heterogeneity analysis.

3.3 Standardized Data Analysis Pipeline

A professional bioinformatics analysis workflow has been established:

Automated quality control: Read quality filtering, adapter trimming, and low-quality base clipping.

Precise alignment: Alignment algorithms optimized for bisulfite-converted sequences

Methylation quantification: Single CpG site methylation level calculation with C/T conversion rate correction.

Statistical analysis: Multiple statistical methods including inter-group differential testing, clustering analysis, and correlation analysis.

Visualization output: Results presented through heatmaps, bar charts, scatter plots, and other visualization formats.

Figure 1. Methylation amplicon detection workflow and technology innovations

4. Application Scenarios and Service Advantages

4.1 Application Scenarios

Methylation amplicon sequencing technology has broad applications across multiple research and clinical fields:

Candidate gene validation: Validation of candidate loci identified by genome-wide methylation screening, with large-sample confirmation studies.

Biomarker development: Development of methylation marker panels for disease diagnosis and prognosis assessment.

Clinical testing applications: Tumor early screening (e.g., SEPT9 methylation detection for colorectal cancer), liquid biopsy (ctDNA methylation analysis).

Drug response prediction: Detection of methylation status in genes related to drug metabolism and drug sensitivity.

Cohort studies: Large-scale population cohort studies on the association between specific gene methylation and disease risk.

Treatment monitoring: Assessment of therapeutic efficacy of demethylating agents (e.g., azacitidine).

Imprinted gene research: Molecular diagnosis of imprinting deficiency syndromes (e.g., Prader-Willi syndrome).

Gene therapy safety evaluation: Monitoring of key gene methylation status in CAR-T cells and gene-edited therapy products to ensure epigenetic stability of therapeutic products.

Cell therapy quality control: Methylation quality control for stem cell therapy and iPSC-derived cell products to assess cell differentiation status and safety.

4.2 Service Advantages

(1) High cost-effectiveness: Over 90% cost reduction compared to whole-genome methods, suitable for large-sample studies.

(2) Ultra-high throughput: Hundreds of samples can be processed in a single run, supporting large-scale clinical cohort studies.

(3) Flexible customization: Supports single-gene tiling design or multi-gene panels, flexibly configured to research needs.

(4) Rapid delivery: Standard service turnaround 3–4 weeks; expedited service available in 2 weeks.

(5) Quality assurance: ISO quality management system certification; positive and negative controls included in every batch.

(6) Professional consultation: Panel design recommendations, data interpretation, and downstream experimental protocol support are provided.

5. Methylation Amplicon Sequencing Analysis Report Examples

We provide detailed and professional methylation amplicon sequencing analysis reports containing the following core components:

(1) Sample QC Information: DNA concentration, purity (A260/A280, A260/A230), and integrity assessment results (RIN score).

(2) Sequencing Data Statistics: Raw/clean read counts, Q30 ratio, and sequencing depth.

(3) Amplicon Coverage Statistics: Mean coverage depth, median coverage depth, and coverage uniformity for each amplicon.

(4) Bisulfite Conversion Efficiency: Conversion efficiency assessed through C-to-T conversion rate in non-CpG context; typically >99%.

(5) Single CpG Site Methylation Levels: Methylation percentage, coverage depth, and standard error for each CpG site.

(6) Regional Average Methylation: Mean methylation level and standard deviation for each amplicon.

(7) Differential Methylation Analysis: Statistical testing of control group vs. experimental group.

(8) Visualization Results: Methylation heatmaps, box plots, and other multi-dimensional displays.

Figure 2. Box plot of methylation levels

Figure 3. Heatmap of methylation levels

(9) ROC Curve Analysis (if applicable): Assessment of diagnostic performance of methylation biomarkers, including AUC, sensitivity, and specificity.

Figure 4. ROC curve for methylation amplicon biomarker

(10) Raw Data: Methylation raw data tables for each sample are provided to support independent downstream data mining.

6. Methylation Amplicon Sequencing Service Contents

*Service Timeline: Standard workflow 3–4 weeks; expedited service 2 weeks

7. Sample Requirements

*Notes: ① For clinical or precious samples, it is recommended to first conduct a small-scale pilot experiment to validate panel efficacy before proceeding to large-scale testing. ② All samples must meet the above quality standards to ensure accuracy and reliability of test results. ③ For special sample types, please contact the GeneRulor technical team in advance (Tel: 400-6309596; Product ordering/technical support: service@generulor.com).

References

[1] Grunau, C., et al. (2001). Bisulfite genomic sequencing: systematic investigation of critical experimental parameters. Nucleic Acids Research, 29(13), E65.

[2] Tusnády, G. E., et al. (2005). BiSearch: primer-design and search tool for PCR on bisulfite-treated genomes. Nucleic Acids Research, 33(1), e9.

[3] Umer, M., & Herceg, Z. (2013). Deciphering the epigenetic code: an overview of DNA methylation analysis methods. Antioxidants & Redox Signaling, 18(15), 1972-1986.

[4] Korshunova, Y., et al. (2008). Massively parallel bisulphite pyrosequencing reveals the molecular complexity of breast cancer-associated cytosine-methylation patterns. Nature Methods, 5(7), 597-599.